AlzeCure Pharma ABFRA:AC6 -6.97%33 PB Ratio is 66.75 as of Jul. 13, 2026. GuruFocus rates FRA:AC6 with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,231 Biotechnology companies, AlzeCure Pharma AB ranks worse than 98.13% on this metric.
The historical rank and industry rank for AlzeCure Pharma AB's PB Ratio or its related term are showing as below:
FRA:AC6'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 71.63
Current: 71.63
During the past 9 years, AlzeCure Pharma AB's highest PB Ratio was 71.63. The lowest was 0.00. And the median was 0.00.
FRA:AC6's PB Ratio is ranked worse than 98.13% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs FRA:AC6: 71.63
During the past 12 months, AlzeCure Pharma AB's average Book Value Per Share Growth Rate was 2.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -33.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -33.80% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of AlzeCure Pharma AB was 28.80% per year. The lowest was -48.60% per year. And the median was -35.25% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
AlzeCure Pharma AB PB Ratio Related Terms
AlzeCure Pharma AB PB Ratio Historical Data
* Premium members only.
The historical data trend for AlzeCure Pharma AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AlzeCure Pharma AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AlzeCure Pharma AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AlzeCure Pharma AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where AlzeCure Pharma AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
AlzeCure Pharma AB (FRA:AC6) has a PB Ratio of 66.75 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on AlzeCure Pharma AB and its competitors. According to the industry distribution chart, AlzeCure Pharma AB ranks #1208 out of 1231 companies in the Biotechnology industry, placing it in the top 98.1%.
Is AlzeCure Pharma AB's PB Ratio too high?
AlzeCure Pharma AB's current PB Ratio is 66.75. The Biotechnology industry median PB Ratio is 2.93. AlzeCure Pharma AB's value of 66.75 is 2178.2% above this industry median. Based on the distribution chart, AlzeCure Pharma AB ranks #1208 out of 1231 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AlzeCure Pharma AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does AlzeCure Pharma AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AlzeCure Pharma AB ranks #1208 out of 1231 companies for PB Ratio. This places AlzeCure Pharma AB in the lower half of its industry. The industry median PB Ratio is 2.93. AlzeCure Pharma AB's value of 66.75 is 2178.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AlzeCure Pharma AB's current PB Ratio of 66.75 is 2178.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on AlzeCure Pharma AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AlzeCure Pharma AB's current PB Ratio is 66.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AlzeCure Pharma AB stock overvalued right now?
AlzeCure Pharma AB (FRA:AC6) has a current PB Ratio of 66.75. The current PB Ratio is 66.75 and 2178.2% above the Biotechnology industry median of 2.93. AlzeCure Pharma AB's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For AlzeCure Pharma AB (FRA:AC6), the current PB Ratio is 66.75 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
33GF Score
Get the complete analysis for FRA:AC6
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AC6 has been successfully added to your 
